Posted by Michael Wonder on 26 Sep 2022
Atea Pharmaceuticals announces U.S. FDA fast track designation granted to AT-752 for treatment of dengue
26 September 2022 - AT-752 is a novel, orally administered, direct-acting antiviral in Phase 2 development for treatment of dengue, showing potent in vitro and in vivo activity in preclinical studies and favourable safety and tolerability in a Phase 1 trial.
Atea Pharmaceuticals today announced that the US FDA has granted fast track designation to AT-752, a novel, orally administered, direct acting anti-viral for the treatment of dengue virus infection.
